Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Taxes: 2023-2025

Historic Change in Taxes for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to $620,000.

  • Entrada Therapeutics' Change in Taxes rose 133.33% to $620,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 172.46%. This contributed to the annual value of -$3.4 million for FY2024, which is 183.42% down from last year.
  • Latest data reveals that Entrada Therapeutics reported Change in Taxes of $620,000 as of Q3 2025, which was up 177.31% from -$802,000 recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Change in Taxes high stood at $7.4 million for Q2 2023, and its period low was -$7.4 million during Q3 2023.
  • For the 3-year period, Entrada Therapeutics' Change in Taxes averaged around $62,000, with its median value being -$333,500 (2025).
  • As far as peak fluctuations go, Entrada Therapeutics' Change in Taxes plummeted by 139.36% in 2024, and later spiked by 133.33% in 2025.
  • Quarterly analysis of 3 years shows Entrada Therapeutics' Change in Taxes stood at $4.0 million in 2023, then slumped by 139.36% to -$1.6 million in 2024, then spiked by 133.33% to $620,000 in 2025.
  • Its Change in Taxes stands at $620,000 for Q3 2025, versus -$802,000 for Q2 2025 and $135,000 for Q1 2025.